Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis - Nature Medicine

  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 20 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 53%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

In an interim analysis of a first-in-human phase 1 trial of patients with neuroblastoma, highly pure GD2-specific CARNKT cells were well tolerated with no observed dose-limiting toxicities. ChildhoodCancerAwarenessMonth

The authors are grateful to M. Brenner, H. Heslop and personnel from the cGMP facility at the Center for Cell and Gene Therapy for manufacturing CAR-NKT cells; A. Sher, K. Kukreja and P. Srivaths; staff of the Flow Cytometry Core Laboratory of the Texas Children’s Cancer and Hematology Center; P. Saha for excellent technical assistance; and E. Chomsky, E. Kiner and H. Sharim for help with scRNA-seq.

Andras Heczey, Amy N. Courtney, Simon Robinson, Ka Liu, Mingmei Li, Nisha Ghatwai, Bin Liu, Cynthia N. Chauvin-Fleurence, Xin Xu, Ho Ngai, Erica J. Di Pierro & Leonid S. MetelitsaAndras Heczey & Leonid S. MetelitsaAndras Heczey, Olga Dakhova & Leonid S. MetelitsaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Is this a new paper? Otherwise, why the link is referring to a paper from 2020 or why are you promoting it now?!!

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 451. in HEALTH

Health Health Latest News, Health Health Headlines